Global Women’s Health Market Driven by Governmental Efforts to Increment Awareness

Published Date : Feb 12, 2018

ALBANY, New York, February 12, 2018 – A recent business intelligence publication on the global market for women’s health is now available at the prestigious repository of The report has projected that the demand in the global women’s health market will increment at a formidable CAGR of 5.7% during the forecast period of 2017 to 2025, which would primarily be a reflection of increasing number of working women across several emerging economies as well as the prevalence of menopausal conditions. The analysts of the report have evaluated that the opportunities in the women’s health market, across the globe, translated into a revenue of US$58.05 bn in 2016.

The report, titled “Women’s Health Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025,” is a comprehensive study compiled by a group of professional and experienced research analysts, aspiring to serve as a decision-making tool for its targeted audiences such as hospitals and clinics, medical research and development companies, medical device companies, women health diagnostics solutions vendors, medical device manufacturers, imaging and diagnostic centers, and investment banks. The report starts with an executive summary on how the demand has evolved in the global women’s health market and where it is headed as well as what are the factors that will determine the demand during the aforementioned forecast period. The analysts of the report have also segmented the market for women’s health on the basis of treatment type and disease indication. In addition to that, the report explores the potential of demand that can be expected from various countries and regions in the near future. To complete a thorough study of the market’s condition, the report contains a dedicated chapter on the competitive landscape of the global women’s health market, wherein several prominent players have been assessed for their business overview including business segments, key financials, recent developments, and strategic decisions.

For Sample Copy, click here:

Some of the key factors augmenting the demand in the global women’s health market are rising incidences of chronic and lifestyle-related disorders in women, high prevalence of infectious diseases in women, and increasing awareness about fertility testing and initiatives taken by government and health organization. In addition to that, increased adoption of point-of-care and rapid diagnostic tests, mushrooming of private diagnostic and imaging centers, and public-private partnerships to enhance the infrastructure of diagnostic imaging centers are also expected to reflect positively over the market. On the other hand, factors such as high cost of diagnostic imaging systems and procedures, stringent regulatory guidelines, increasing adoption of refurbished diagnostic imaging systems, and shortage of skilled laboratory technicians are obstructing the market for women’s health from flourishing. That being said, the vendors of this market are expected to gain new opportunities from improving healthcare infrastructure in various emerging economies as well as growing number of regulatory approvals for immunoassay diagnostic techniques.

Based on treatment type, the global women’s health market has been segmented into hormonal treatment including progestin therapy, estrogen therapy, combination therapy, parathyroid hormone therapy, thyroid replacement therapy, and others and non-hormonal treatment, which has been further sub-segmented into targeted therapy drugs, biophosphonates, antibiotics, and others. Based on disease indication, the women’s health market has been bifurcated into cancer including cervical cancer, breast cancer, and ovarian cancer, hypothyroidism, post-menopausal syndrome, contraceptive, osteoporosis, urinary tract, uterine fibroid, infection, and others.

The report has profiled a number of key companies currently ahead of the curve in the global women’s health market, such as Novartis AG, Eli Lilly and Company, Merck & Co., Inc., Pfizer, Inc., Novo Nordisk A/S, Lupin Pharmaceuticals, Inc., Amgen Inc., AstraZeneca, Sanofi, Allergan Plc, F. Hoffmann-La Roche Ltd., Bayer AG, Johnson & Johnson, and GlaxoSmithKline plc.

To order report Call Toll Free: 866-997-4948 or send an email on